Sai Parenteral's Limited IPO Review
Neutral372-392 · Mainboard
✦
Analyst Verdict
Sai Parenteral's Limited IPO
Neutral
IPO at a Glance
Price Band
372-392
Issue Size
409cr
Min. Investment
₹14,896
Opens
2026-03-22
Closes
2026-03-25
Listing
2026-03-31
Category
Mainboard
Key Strengths
✓Diversified pharma portfolio across branded generics and CDMO services
✓Strong capabilities in sterile injectable manufacturing
✓Presence across multiple therapeutic areas and dosage forms
✓Promoter-led management with a long operating track record
✓Multiple manufacturing facilities supported by in-house R&D
Key Risks
⚠High revenue dependence on injectable formulations
⚠Manufacturing facilities are concentrated in limited geographies
⚠Exposure to stringent regulatory inspections and compliance risks
⚠Dependence on third-party suppliers for key raw materials
⚠Customer concentration may affect revenue stability
Frequently Asked Questions
Should I apply for Sai Parenteral's Limited IPO?
Based on our analysis, our rating for Sai Parenteral's Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Sai Parenteral's Limited IPO?
High revenue dependence on injectable formulations Manufacturing facilities are concentrated in limited geographies Exposure to stringent regulatory inspections and compliance risks
What are the strengths of Sai Parenteral's Limited IPO?
Diversified pharma portfolio across branded generics and CDMO services Strong capabilities in sterile injectable manufacturing Presence across multiple therapeutic areas and dosage forms
What is the price band of Sai Parenteral's Limited IPO?
The price band for Sai Parenteral's Limited IPO is 372-392. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more